Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21873382 | 1.00 | CHRM1 (0.65) | CHRM1PDE2APDE11A | |
| SCHEMBL31668928 | 0.91 | CHRM1 (0.62) | CHRM1 | |
| SCHEMBL21873404 | 0.91 | CHRM1 (0.62) | CHRM1 | |
| SCHEMBL21873461 | 0.91 | CHRM1 (0.63) | CHRM1PDE2APDE11A | |
| SCHEMBL30427826 | 0.91 | CHRM1 (0.63) | CHRM1PDE2APDE11A | |
| SCHEMBL21873423 | 0.89 | CHRM1 (0.59) | CHRM1PDE2APDE11A | |
| SCHEMBL31668986 | 0.89 | CHRM1 (0.59) | CHRM1PDE2APDE11A | |
| SCHEMBL12072487 | 0.89 | CHRM1 (0.64) | CHRM1PDE2APDE11A | |
| SCHEMBL21935412 | 0.89 | CHRM1 (0.71) | CHRM1 | |
| SCHEMBL21935673 | 0.86 | CHRM1 (0.62) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378256-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378256-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | CHRM1 817/4885PDE2A 115/4885PDE11A 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.